NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

ASH Annual Meeting 2024 - Sara Majocchi -

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer